Abstracts tagged "Adalimumab and juvenile idiopathic arthritis (JIA)"

Abstract Number: 385 • 2016 ACR/ARHP Annual Meeting
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Gerd Horneff¹, Marieke M. B. Seyger², Dilek Arikan³, Jasmina Kalabic⁴, Jaclyn K. Anderson³, Andreas Lazar⁵, David A. Williams³, Chen Wang³, Rita Tarzynski-Potempa³ and Jeffrey S. Hyams⁶, ¹Asklepios Kliniken GmbH, Hamburg, Germany, ²Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Deutschland GmbH & Co. KG, North ChicagoLudwigshafen, IL, Germany, ⁶Connecticut Children’s Medical Center, Hartford, CT
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…
Abstract Number: 2452 • 2015 ACR/ARHP Annual Meeting
Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab
Daniel J. Kingsbury¹, Pierre Quartier², G Horneff³, Kirsten Minden⁴, Mary Toth⁵, Nupun A. Varothai⁶, Anabela Cardoso⁷ and Jasmina Kalabic⁶, ¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ²Hopital Necker-Enfants Malades, Paris, France, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ⁵Akron Children's Hospital, Akron, OH, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Amadora, Portugal
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) is increasingly accepted for defining a treat-to-target strategy in patients (pts) with juvenile idiopathic arthritis (JIA)1 The…
Abstract Number: 2428 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis
Daniel Lovell^1,2, Nicolino Ruperto³, Andreas Reiff⁴, Lawrence Jung⁵, Katerina Jarosova⁶, Pierre Quartier⁷, Christy Sandborg⁸, John F. Bohnsack⁹, Dirk Elewaut¹⁰, Ivan Foeldvari¹¹, Joseph Rovensky¹², Edward H. Giannini², Nupun A. Varothai¹³, Jasmina Kalabic¹³ and Alberto Martini^14,15,16, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ⁴Children's Hospital, Los Angeles, CA, ⁵Pediatric Rheumatology, Children's National Med Ctr, Washington, DC, ⁶Revmatologicky ustav, Prague, Czech Republic, ⁷Hospital Necker Enfants Malades, Paris, France, ⁸Stanford University Medical Center, Standford, CA, ⁹Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁰Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ¹¹Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹²The National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹³AbbVie, North Chicago, IL, ¹⁴University of Genova, Genova, Italy, ¹⁵Department of Pediatrics, University of Genova, Genova, Italy, ¹⁶Istituto Gaslini-PRINTO, Genova, Italy
Background/Purpose: The diagnosis of polyarticular JIA (pJIA) is made in childhood but the disease and the diagnosis are carried into adulthood. Adults with pJIA have…
Abstract Number: 279 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Adalimumab In Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 To <4 Years Or ≥4 Years Weighing <15 Kg
Daniel J. Kingsbury¹, Pierre Quartier², Vipin Arora³, Jasmina Kalabic⁴, Hartmut Kupper⁴ and Neelufar Mozaffarian³, ¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ²Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ³AbbVie, North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe juvenile idiopathic arthritis (JIA) in patients (pts) ≥4 years (yrs) old in the US,…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.